March 31, 2025Published by TDP on March 31, 2025Categories ChemotherapyPromising AVO Therapy with Acalabrutinib and Venetoclax for High-Risk CLL PatientsExplore the AVO regimen for high-risk CLL patients, including the role of BTK inhibitors and time-limited therapies. Gain insights into tailored treatment strategies.